# MolecuLight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moleculight

- Industry: Medical Devices & Equipment
- Headquarters: Toronto, Canada
- Website: www.moleculight.com
- Total disclosed funding: $16M
- Latest round: Series C (Aug 15, 2024)
- Investors on record: 4

## About

Founded in 2013 and based in Toronto, Canada, MolecuLight Inc. is a medical imaging company that develops a non-invasive optical technology for point-of-care wound analysis. The company's device provides real-time bacteriological information. As of 2024, the company is headed by its CEO Anil Amlani. In January 2025, MolecuLight Inc. raised USD 27.5 million in venture funding from new investor Hayfin Capital Management.

MolecuLight offers two primary devices including the MolecuLight i® and MolecuLight DX™. These point-of-care imaging devices utilize fluorescence technology to detect bacterial loads and measure wound dimensions. The MolecuLight I allows clinicians to visualize bacteria and accurately assess wounds at the point of care, facilitating informed treatment decisions and improving patient outcomes. The MolecuLight DX complements this by providing enhanced imaging capabilities for more detailed wound analysis.

The company plans to use the January 2025 funding to support its growth and research and development pipeline.

## Funding rounds

- Series C, Aug 15, 2024, $12M — Export Development Canada, Prosegur Ventures, Azahar Private Capital
- Seed, May 29, 2014, $4M — iGan Partners

## Investors

- iGan Partners (https://capitalatlas.ai/funds/igan-partners) — Seed
- Export Development Canada — Series C
- Prosegur Ventures (https://capitalatlas.ai/funds/prosegur-ventures) — Series C
- Azahar Private Capital (https://capitalatlas.ai/funds/azahar-private-capital) — Series C